Liposomal NMN Outperforms Standard NMN in Boosting NAD+ Levels

Nicotinamide mononucleotide (NMN) is a direct precursor to NAD+, the essential coenzyme that fuels cellular energy, DNA repair, and longevity pathways. As NAD+ levels decline with age, supplementation has become a focal point for supporting metabolic health and healthy aging. However, not all NMN supplements deliver the same level of effectiveness.

A recent human clinical study directly compared Liposomal NMN, Standard NMN, and a placebo, demonstrating that liposomal delivery significantly outperforms non-liposomal NMN in elevating NAD+ levels.

Key Findings from the Study


Liposomal NMN increased blood NAD+ levels by 84% within four weeks


It was significantly more effective than Standard NMN at raising NAD+


NAD+ levels remained above baseline even four weeks after stopping Liposomal NMN

Clinical Trial: Evaluating the Efficacy of Liposomal NMN


A double-blind, placebo-controlled clinical trial was conducted with 15 healthy men aged 40 and older to measure the effects of NMN supplementation. Participants were randomly assigned to one of three groups (5 per group) and took their assigned supplement daily after breakfast for four weeks.

  • Placebo Group: Maltodextrin (4g/day)
  • Standard NMN Group: Non-liposomal NMN (350 mg/day)
  • Liposomal NMN Group: Liposomal NMN (350 mg/day)


Blood NAD+ levels were measured at four time points:

1. Before supplementation (baseline)
2. One hour after the first dose
3. After four weeks of daily supplementation
4. Four weeks after stopping supplementation

This study design allowed researchers to assess not just how effectively each form of NMN raised NAD+ levels, but also how long those effects persisted after supplementation ended.

  • Illustration of Liposomal NMN Absorption.

    NMN is encapsulated in a fat-based liposome, which merges with the cell membrane to deliver NMN directly inside. This process enhances absorption, protects NMN from degradation, and improves its effectiveness compared to standard NMN supplements.

  • Liposomal NMN Increased Blood NAD+ Levels By 84%

    After four weeks of supplementation, the Liposomal NMN Group exhibited an 84% increase in blood NAD+ levels, rising from 28.6 µM (baseline) to 52.5 µM.

    Although NAD+ levels declined four weeks after participants stopped supplementation, they remained elevated at 36 µM compared to the baseline of 28.6 µM.

    This figure illustrates that supplementation with Liposomal NMN significantly increased NAD+ levels after four weeks, compared to both pre-supplementation and one hour post-intake. After stopping supplementation, NAD+ levels were decreased at 8 weeks, though they remained higher than baseline.

  • Encapsulated NMN Boosted NAD+ More Effectively Than Standard NMN

    Among all groups, Liposomal NMN produced the greatest increase in NAD+ levels after four weeks, outperforming both Standard NMN and placebo.

    This figure shows that the Liposomal NMN Group (orange bar) had significantly higher NAD+ levels than the Non-Liposomal Group (green bar) and the Placebo Group (blue bar).

    “This shows that liposomal NMN promotes the production of NAD+ significantly more than both groups.”

Conclusion

A four-week course of Liposomal NMN led to a significant increase in NAD+ production compared to Standard NMN.

“It was found that the liposomal NMN group produced significantly more NAD+ in the fourth week of intake.”

These results confirm that encapsulated NMN is a more effective method for increasing NAD+ levels.

“In the results of this study, liposomal NMN significantly increased NAD+ compared to non-liposomal NMN.”